Aitia Entered into a Drug Discovery Collaboration with UCB to Discover New Therapies for Huntington's Disease
- The companies collaborated to discover and validate novel drug targets and drug candidates causally linked to clinical endpoints for Huntington's disease
- The collaboration will use the novel drug targets for Huntington's disease from Aitia's Gemini Digital Twins with UCB's expertise in drug research and preclinical model systems in neurodegeneration to advance the discovery of new therapies for HD
- Additionally, Aitia is exposing the hidden biological mechanisms of disease to develop Digital Twins of disease in oncology, immunology, and neurodegenerative diseases by using the convergence of multi-omic patient data, high-performance computing, and causal learning and AI
Ref: PRNewswire | Image: Aitia
Related News:- UCB’s Fintepla (fenfluramine) Receive EU Approval for Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].